MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.

MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
Toxicol Lett. 2013 Jun 13;
Authors: Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B
Abstract
Histone deacetylase (HDAC) inhibitors have recently emerged as a new class of anti-cancer agents. Trichostatin A (TSA), a classical HDAC inhibitor, has been demonstrated to induce cell cycle arrest, promote cell apoptosis, and inhibit metastasis. However, the molecular mechanism underlying TSA function has not been fully elucidated. In the current study, we found that TSA treatment induced altered expression of cell cycle-associated genes in HCT116 cells by RT-PCR array. Among the 84 genes related to cell cycle control, 34 genes were significantly altered by TSA treatment, with 7 genes upregulated and 27 genes downregulated. Interestingly, gene expression of minichromosome maintenance protein-2 (MCM-2) was significantly downregulated by TSA treatment. This was confirmed by quantitative RT-PCR and Western blotting. Moreover, silencing of MCM-2 by siRNA led to cell cycle arrest and apoptosis in HCT116 cells. In addition, TSA caused an increase of phosphorylated JNK, which was involved in downregulation of MCM-2. Together, our results suggest that MCM-2 is a noval therapeutic target of TSA in colon cancer cells.
PMID: 23770000 [PubMed - as supplied by publisher]

Source: Toxicology Letters - June 13, 2013 Category: Toxicology Authors: Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B Tags: Toxicol Lett Source Type: research